3.4.22.26 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16269926&form=6&db=m Cancer procoagulant in patients with adenocarcinomas. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.22.26 Blood Coagulation Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16171148&form=6&db=m [Cancer procoagulant (CP)] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,2 3.4.22.26 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10656610&form=6&db=m Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.22.26 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22718627&form=6&db=m The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310878&form=6&db=m Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2298496&form=6&db=m Cancer procoagulant in serum of rats during development of experimental epithelioma. ongoing research,unassigned 4,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2501168&form=6&db=m Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma. therapeutic application,unassigned 1,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3294610&form=6&db=m Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3530904&form=6&db=m gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. causal interaction,therapeutic application,unassigned 3,1,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3933592&form=6&db=m Cysteine proteinase procoagulant from amnion-chorion. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3935163&form=6&db=m Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7016920&form=6&db=m A factor X-activating cysteine protease from malignant tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7016982&form=6&db=m A proteolytic procoagulant associated with malignant transformation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.22.26 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15600294&form=6&db=m [Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.22.26 Carcinosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17061060&form=6&db=m Effect of immunisation with cancer procoagulant on the growth of Walker 256 carcinosarcoma cells in rats. ongoing research,unassigned 3,0 3.4.22.26 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10870414&form=6&db=m [Diagnostic significance of cancer procoagulant activity in colorectal cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.22.26 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10870414&form=6&db=m [Diagnostic significance of cancer procoagulant activity in colorectal cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.22.26 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11761814&form=6&db=m [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.22.26 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11820560&form=6&db=m Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.22.26 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630007&form=6&db=m Antioxidant potential in esophageal, stomach and colorectal cancers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.22.26 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11143939&form=6&db=m [Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.22.26 Disseminated Intravascular Coagulation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757074&form=6&db=m Haemostatic problems in acute promyelocytic leukaemia. causal interaction,ongoing research,unassigned 1,1,0 3.4.22.26 Esophageal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11398511&form=6&db=m [Diagnostic value of testing the procoagulant activity of neoplasms in cases of stomach and esophageal neoplasms] diagnostic usage,unassigned 4,0 3.4.22.26 Esophageal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630007&form=6&db=m Antioxidant potential in esophageal, stomach and colorectal cancers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.22.26 Gastrointestinal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630007&form=6&db=m Antioxidant potential in esophageal, stomach and colorectal cancers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.22.26 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10896200&form=6&db=m Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. causal interaction,ongoing research,unassigned 2,3,0 3.4.22.26 Leiomyoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16122189&form=6&db=m The activity of cancer procoagulant in cases of uterine leiomyomas. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.22.26 Leiomyoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17139986&form=6&db=m Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2209822&form=6&db=m Cancer procoagulant in acute lymphoblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3355894&form=6&db=m A new procoagulant in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8289480&form=6&db=m Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. ongoing research,unassigned 4,0 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578472&form=6&db=m Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. causal interaction,unassigned 3,0 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9639510&form=6&db=m Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.22.26 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31434194&form=6&db=m Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage. ongoing research,unassigned 1,0 3.4.22.26 Leukemia, Lymphoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2274915&form=6&db=m Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.22.26 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8289480&form=6&db=m Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. ongoing research,unassigned 4,0 3.4.22.26 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578472&form=6&db=m Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. causal interaction,unassigned 3,0 3.4.22.26 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9639510&form=6&db=m Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.22.26 Leukemia, Promyelocytic, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31434194&form=6&db=m Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage. ongoing research,unassigned 1,0 3.4.22.26 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9241361&form=6&db=m Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.22.26 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337542&form=6&db=m Cancer procoagulant (CP) in lung cancer. ongoing research,unassigned 3,0 3.4.22.26 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2870391&form=6&db=m Cancer procoagulant and haemostatic abnormalities in melanoma. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.22.26 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3530903&form=6&db=m Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin? causal interaction,ongoing research,unassigned 2,2,0 3.4.22.26 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3536081&form=6&db=m Cancer procoagulant in human tumor cells: evidence from melanoma patients. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.22.26 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19419757&form=6&db=m Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.22.26 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19448531&form=6&db=m Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.22.26 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12098000&form=6&db=m Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.22.26 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3530903&form=6&db=m Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin? causal interaction,ongoing research,unassigned 2,2,0 3.4.22.26 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11820560&form=6&db=m Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.22.26 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16608038&form=6&db=m Usefulness of examination of some tumor markers in diagnostics of liver cancer. unassigned - 3.4.22.26 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26341972&form=6&db=m The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation. causal interaction,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=234638&form=6&db=m Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=285292&form=6&db=m Comparison of procoagulant activities in extracts of normal and malignant human tissue. diagnostic usage,ongoing research,unassigned 4,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1310878&form=6&db=m Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1575750&form=6&db=m The purification and properties of cancer procoagulant from murine tumors. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1688361&form=6&db=m Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1728616&form=6&db=m Blood coagulation changes in nude mice bearing human colon carcinomas. causal interaction,unassigned 2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1799660&form=6&db=m The site of activation of factor X by cancer procoagulant. causal interaction,ongoing research,unassigned 3,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1829933&form=6&db=m Early detection of relapse in acute non-lymphoblastic leukaemia patients by cancer procoagulant assay. diagnostic usage,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2003736&form=6&db=m [Paraneoplastic syndrome hematologic abnormalities] unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2169340&form=6&db=m An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. causal interaction,diagnostic usage,therapeutic application,unassigned 4,3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2209822&form=6&db=m Cancer procoagulant in acute lymphoblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2274915&form=6&db=m Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. causal interaction,diagnostic usage,ongoing research,unassigned 1,4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2298496&form=6&db=m Cancer procoagulant in serum of rats during development of experimental epithelioma. ongoing research,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2501168&form=6&db=m Evidence of a warfarin-sensitive cancer procoagulant in V2 carcinoma. therapeutic application,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2617480&form=6&db=m Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2772865&form=6&db=m Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. therapeutic application,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2804124&form=6&db=m Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2870391&form=6&db=m Cancer procoagulant and haemostatic abnormalities in melanoma. causal interaction,diagnostic usage,unassigned 2,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3166906&form=6&db=m Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation. causal interaction,therapeutic application,unassigned 1,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3209584&form=6&db=m Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells. ongoing research,therapeutic application,unassigned 4,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3294610&form=6&db=m Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3355894&form=6&db=m A new procoagulant in acute leukemia. causal interaction,diagnostic usage,ongoing research,unassigned 1,1,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3530903&form=6&db=m Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin? causal interaction,ongoing research,unassigned 2,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3530904&form=6&db=m gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant. causal interaction,therapeutic application,unassigned 3,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3536081&form=6&db=m Cancer procoagulant in human tumor cells: evidence from melanoma patients. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3899178&form=6&db=m Comparison of properties of cancer procoagulant and human amnion-chorion procoagulant. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3933592&form=6&db=m Cysteine proteinase procoagulant from amnion-chorion. causal interaction,diagnostic usage,ongoing research,unassigned 3,1,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3935163&form=6&db=m Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6398243&form=6&db=m Cancer cell procoagulants and their pharmacological modulation. causal interaction,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7016920&form=6&db=m A factor X-activating cysteine protease from malignant tissue. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7016982&form=6&db=m A proteolytic procoagulant associated with malignant transformation. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7845233&form=6&db=m Cancer procoagulant. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7944389&form=6&db=m Effect of divalent ions on the activity of cancer procoagulant. ongoing research,unassigned 2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8052963&form=6&db=m New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors. diagnostic usage,therapeutic application,unassigned 3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8055461&form=6&db=m Application of cancer procoagulant as an early detection tumor marker. causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8220153&form=6&db=m New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8289480&form=6&db=m Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. ongoing research,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8329571&form=6&db=m Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8578472&form=6&db=m Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. causal interaction,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8646671&form=6&db=m Diagnosis of cancer-associated vascular disorders. causal interaction,diagnostic usage,ongoing research,unassigned 3,2,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9241361&form=6&db=m Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. diagnostic usage,ongoing research,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9259116&form=6&db=m Cancer procoagulant activity studies using synthetic peptidyl substrates. ongoing research,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337529&form=6&db=m Cancer procoagulant--CP. causal interaction,therapeutic application,unassigned 2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9337542&form=6&db=m Cancer procoagulant (CP) in lung cancer. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9466566&form=6&db=m Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,4,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9518049&form=6&db=m Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. diagnostic usage,ongoing research,unassigned 1,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9554535&form=6&db=m Generation of a monoclonal antibody that inhibits the procoagulant activity of various cancer cell lines. therapeutic application,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9601860&form=6&db=m [Activation of blood coagulation in oncology patients] causal interaction,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9639510&form=6&db=m Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. causal interaction,ongoing research,unassigned 3,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10326766&form=6&db=m Cancer procoagulant stimulates platelet adhesion. diagnostic usage,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10656610&form=6&db=m Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. diagnostic usage,therapeutic application,unassigned 4,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10870414&form=6&db=m [Diagnostic significance of cancer procoagulant activity in colorectal cancer] causal interaction,diagnostic usage,ongoing research,therapeutic application 1,4,3,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10896200&form=6&db=m Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. causal interaction,ongoing research,unassigned 2,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10967923&form=6&db=m [Cancer procoagulant (CP): the new biochemical marker in oncologic diagnosis] causal interaction,diagnostic usage,therapeutic application,unassigned 2,4,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11079152&form=6&db=m Thrombosis in cancer patients. causal interaction,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11127398&form=6&db=m Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,3 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11143939&form=6&db=m [Expression of thrombogenic substances by neoplasms: TF and cancer procoagulant. Pathogenic effects.] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11398511&form=6&db=m [Diagnostic value of testing the procoagulant activity of neoplasms in cases of stomach and esophageal neoplasms] diagnostic usage,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11431105&form=6&db=m Cancer procoagulant and blood platelet activation. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11549774&form=6&db=m Update on tumor cell procoagulant factors. therapeutic application,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11674861&form=6&db=m Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant. ongoing research,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11761814&form=6&db=m [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer] diagnostic usage,ongoing research,therapeutic application,unassigned 2,3,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11820560&form=6&db=m Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,4,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11908507&form=6&db=m Cancer and the prothrombotic state. diagnostic usage,unassigned 2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11990487&form=6&db=m Biochemistry of cancer procoagulant. causal interaction,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12023851&form=6&db=m Coagulation proteases and human cancer. causal interaction,therapeutic application,unassigned 3,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12098000&form=6&db=m Assessment of coagulation disorders and cancer procoagulant activity in patients with myelodysplastic syndromes. causal interaction,diagnostic usage,therapeutic application,unassigned 3,4,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12234564&form=6&db=m Cancer and thromboembolic disease: pathogenic mechanisms. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12630007&form=6&db=m Antioxidant potential in esophageal, stomach and colorectal cancers. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12888932&form=6&db=m Pathogenesis of increased risk of thrombosis in cancer. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14648973&form=6&db=m [Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers] diagnostic usage,unassigned 4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15009464&form=6&db=m Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines. diagnostic usage,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15182825&form=6&db=m The prothrombotic state in cancer: pathogenic mechanisms. ongoing research,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15246868&form=6&db=m Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies. causal interaction,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15600294&form=6&db=m [Cancer procoagulant activity in serum and neoplastic tissue in cases of cervical and uterine carcinoma] causal interaction,diagnostic usage,ongoing research,unassigned 1,4,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15837545&form=6&db=m Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. causal interaction,ongoing research,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16029967&form=6&db=m Intravascular clotting activation and bleeding in patients with hematologic malignancies. causal interaction,therapeutic application,unassigned 2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16122189&form=6&db=m The activity of cancer procoagulant in cases of uterine leiomyomas. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16124376&form=6&db=m [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16171148&form=6&db=m [Cancer procoagulant (CP)] causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,2 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16269926&form=6&db=m Cancer procoagulant in patients with adenocarcinomas. causal interaction,diagnostic usage,unassigned 3,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16363277&form=6&db=m [Malignancy and thrombosis: a double-sided clinical relationship] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16379335&form=6&db=m [Assessment of the efficacy of cancer procoagulant (CP) activity evaluation in the oncological diagnosis of the urinary system] diagnostic usage,therapeutic application,unassigned 4,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16608038&form=6&db=m Usefulness of examination of some tumor markers in diagnostics of liver cancer. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16757074&form=6&db=m Haemostatic problems in acute promyelocytic leukaemia. causal interaction,ongoing research,unassigned 1,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17017477&form=6&db=m [Usefulness of detecting cancer procoagulant activity and thyrotropic hormone concentration in the differentiation of tumor-like changes in the thyroid] causal interaction,diagnostic usage,ongoing research,unassigned 3,3,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17061060&form=6&db=m Effect of immunisation with cancer procoagulant on the growth of Walker 256 carcinosarcoma cells in rats. ongoing research,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17139986&form=6&db=m Analysis of the relationship between cancer procoagulant activity and PCNA and Ki-67 expression in cases of common and cellular uterine leiomyomas. causal interaction,diagnostic usage,ongoing research,unassigned 2,4,3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17852460&form=6&db=m Procoagulant factors in patients with cancer. causal interaction,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18589871&form=6&db=m Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18632433&form=6&db=m Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18640896&form=6&db=m [Chemotherapeutics increasing the risk of thromboembolic complications. The necessity of anticoagulant profilaxis during chemotherapy] causal interaction,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18992924&form=6&db=m Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19419757&form=6&db=m Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19448531&form=6&db=m Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20013532&form=6&db=m Prostate-specific antigen, prostate cancer, and disorders of hemostasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20505748&form=6&db=m The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,2,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21458031&form=6&db=m All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21503574&form=6&db=m Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,3,1 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22682081&form=6&db=m Functional protease profiling with reporter peptides in serum specimens of colorectal cancer patients: demonstration of its routine diagnostic applicability. diagnostic usage,ongoing research,unassigned 4,2,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22718627&form=6&db=m The effect of cancer procoagulant on expression of metastatic and angiogenic markers in breast cancer and embryonic stem cell lines. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25712535&form=6&db=m Thrombosis in leukemia: incidence, causes, and practical management. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25917036&form=6&db=m [Functions of inflammatory factor in non-tumor deep venous thrombosis of lower extremity]. causal interaction,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26034387&form=6&db=m Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro. diagnostic usage,ongoing research,unassigned 3,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26341972&form=6&db=m The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation. causal interaction,unassigned 3,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27419881&form=6&db=m The Pathogenetic Role of Apoptosis in Hypercoagulable States. ongoing research,therapeutic application,unassigned 3,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29075790&form=6&db=m Differential contribution of tissue factor and Factor XII to thrombin generation triggered by breast and pancreatic cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29411223&form=6&db=m In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31434194&form=6&db=m Syncope as Initial Presentation in an Undifferentiated Type Acute Myeloid Leukemia Patient with Acute Intracranial Hemorrhage. ongoing research,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31874669&form=6&db=m [Perioperative Venous Thromboembolism (VTE) Prophylaxis in Thoracic Cancer Patients: Chinese Experts Consensus - Interpretation of Perioperative Hypercoagulable State]. causal interaction,unassigned 1,0 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32877229&form=6&db=m Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. unassigned - 3.4.22.26 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33990129&form=6&db=m Cancer-Related Venous Thromboembolism: From Pathogenesis to Risk Assessment. causal interaction,unassigned 1,0 3.4.22.26 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14648973&form=6&db=m [Evaluation of diagnostic values of neoplastic procoagulant in pancreatic, hepatic and ovary cancers] diagnostic usage,unassigned 4,0 3.4.22.26 Paraproteinemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18992924&form=6&db=m Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. causal interaction,diagnostic usage,unassigned 1,2,0 3.4.22.26 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1688361&form=6&db=m Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity. diagnostic usage,ongoing research,unassigned 2,1,0 3.4.22.26 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2209822&form=6&db=m Cancer procoagulant in acute lymphoblastic leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,2 3.4.22.26 Thromboembolism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18632433&form=6&db=m Venous thromboembolism in patients with cancer and its relationship to the coagulation cascade and vascular endothelial growth factor. causal interaction,diagnostic usage,unassigned 4,4,0 3.4.22.26 Thrombophilia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16363277&form=6&db=m [Malignancy and thrombosis: a double-sided clinical relationship] causal interaction,diagnostic usage,unassigned 4,4,0 3.4.22.26 Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25712535&form=6&db=m Thrombosis in leukemia: incidence, causes, and practical management. unassigned - 3.4.22.26 Urinary Bladder Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16124376&form=6&db=m [Cancer procoagulant and cathepsin D activity in blood serum in patients with bladder cancer] diagnostic usage,ongoing research,unassigned 4,4,0 3.4.22.26 Venous Thrombosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25917036&form=6&db=m [Functions of inflammatory factor in non-tumor deep venous thrombosis of lower extremity]. causal interaction,unassigned 1,0